Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

Effective Date: 11/7/2019

Denosumab (Prolia®/Xgeva®)


HCPCS:  J0897

Benefit:  Medical

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

A. Coverage of the requested drug is provided when all the following are met:
   a. For the prevention of skeletal-related events in patients with multiple myeloma or with bone metastases from solid tumors (Xgeva only) when the below criteria are met:
      i. Documentation that at least one IV bisphosphonate has been ineffective, not tolerated or contraindicated
         OR
      ii. National Comprehensive Cancer Network (NCCN) supported category 1 preferred agent for prevention of skeletal related events in patients with bone metastases for the specific oncological diagnosis
         AND
      iii. Patient will supplement with calcium 1000 mg daily and at least 400 IU vitamin D daily
         OR
   b. For the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (Xgeva only) when these criteria have been met:
      i. Documentation of confirmed giant cell tumor of bone and radiologic evidence of measurable disease (via CT scan or MRI)
      ii. Bone is unresectable or surgical resection is likely to result in severe morbidity
      iii. Patient will supplement with calcium 1000 mg daily and at least 400 IU vitamin D daily
         OR
   c. For the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy (Xgeva only)
      i. Diagnosis of hypercalcemia secondary to a malignancy (including hematologic malignancies)
      ii. Albumin corrected serum calcium (CSC) ≥ 12 mg/dL (3.0 mmol/L)
      iii. Documentation that at least one IV bisphosphonate has been ineffective, not tolerated or contraindicated
         OR
d. For the treatment of osteoporosis (Prolia only) when all of the criteria below are met:
   i. BMD T-score at or below -2.5 at the lumbar spine or total hip
   ii. At least one bisphosphonate (if patient has intolerance to oral administration, IV administration will be required) is not effective after at least a 24 month treatment period based on objective documentation except if:
      1. Bisphosphonates (oral and intravenous formulations) are contraindicated
   iii. Patient will supplement with calcium 1000 mg daily and at least 400 IU vitamin D daily
   iv. Will NOT be used in combination with any anabolic bone modifying agent

OR

e. To increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer OR women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer when all of the criteria below are met (Prolia only):
   i. When the 10-year probability of hip fracture is ≥ 3% or the 10-year probability of a major osteoporosis-related fracture is ≥ 20%.
   ii. At least one bisphosphonate (if patient has intolerance to oral administration, IV administration will be required) is not effective after at least a 24 month treatment period based on objective documentation except if:
      1. Bisphosphonates (oral and intravenous formulations) are contraindicated
   iii. Patient will supplement with calcium 1000 mg daily and at least 400 IU vitamin D daily

f. Trial and failure of the preferred products as specified in the BCBSM/BCN medical utilization management drug list.

B. Quantity Limitations, Authorization Period and Renewal Criteria
   a. Quantity Limits:
      i. For all FDA approved indications for Prolia, quantity limit of 60 mg administered once every 6 months
      ii. For the prevention of skeletal-related events in patients with multiple myeloma or with bone metastases from solid tumors (Xgeva), quantity limit of 120 mg administered once every 4 weeks
      iii. For the treatment of giant cell tumor of bone (Xgeva), quantity limit of three 120 mg doses for the first month, followed by 120 mg every 4 weeks
      iv. For the treatment of hypercalcemia of malignancy (Xgeva), quantity limit of three 120 mg doses for the first month, followed by 120 mg every 4 weeks
   b. Renewal Criteria:
      i. Xgeva (multiple myeloma or bone metastases from solid tumors and breast cancer): If more than 1 fracture in the last 6 months alternative therapy is recommended
      ii. Xgeva (giant cell tumor of the bone): Goals of therapy have been met
      iii. Xgeva (hypercalcemia of malignancy): Decrease in albumin CSC levels from baseline
      iv. Prolia: Documentation of improved or stable T-scores while on Prolia

C. Denosumab is considered investigational when used for all other conditions, including but not limited to:
   a. Patients with contraindications to denosumab
   b. Prevention of osteoporosis
   c. Rheumatoid arthritis
   d. Systemic Lupus Erythematosus
   e. Hypercalcemia secondary to diseases other than malignancies

***Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at http://www.cms.hhs.gov/. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.
Therapeutic considerations:

A. FDA approved indication/Diagnosis
   a. Prolia:
      i. Treatment of postmenopausal women with osteoporosis at high risk for fracture
      ii. Treatment to increase bone mass in men with osteoporosis at high risk for fracture
      iii. Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
      iv. Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
      v. Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
   b. Xgeva:
      i. Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
      ii. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
      iii. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

   *Please refer to most recent prescribing information.

B. Background Information
   a. Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor-kB ligand (RANKL)
   b. RANKL is a cytokine that is essential for the formation, function, and survival of osteoclasts
   c. By binding RANKL, denosumab prevents the interaction of RANKL with its receptor on osteoclasts and osteoclasts precursors and reversibly inhibits osteoclast-mediated bone resorption
   d. As a monoclonal antibody, denosumab has potential safety risks/significant safety concerns that must be balanced against its potential benefits
   e. For osteoporosis, treatment should be considered if the 10-year risk is 3% or more for hip fracture or 20% or more for “major” osteoporosis-related fracture based on the US-adapted WHO algorithm
   f. Bisphosphonate treatment for prevention of bone loss, regardless of cause, is the standard of care due to the body of evidence supporting efficacy and track record of safety
   g. Prevention of Osteoporosis Due to Hormone Suppression:
      i. In breast and prostate cancer patients on hormone suppression therapy, hormone suppression increases bone turnover and decreases bone mineral density (BMD)
      ii. Oral bisphosphonates are the best value for the prevention of osteoporosis in patients on hormone suppression therapy
      iii. For prevention of osteoporosis in patients with prostate cancer during androgen deprivation therapy (ADT), there is evidence that denosumab, pamidronate, zoledronic acid, and alendronate increase BMD during ADT
      iv. NCCN prostate cancer guidelines recommend zoledronic acid once annually or alendronate 70 mg weekly when risk of fracture warrants treatment
      v. Bisphosphonate treatment for the prevention of bone loss, regardless of cause, is the standard of care due to the body of evidence supporting efficacy and track record of safety
   h. Cancer-Related Bone Metastases:
      i. Zoledronic acid provides the best value for prevention of skeletal complications, decreasing the incidence and rate of skeletal events, and delaying skeletal events in women with breast cancer with bone metastases
      ii. Denosumab and zoledronic acid appear to be at least similar in delaying the time to first skeletal related event in patients with metastasis from solid tumor cancers
   i. Hypercalcemia of Malignancy:
      i. HCM is a serious complication that is indicative of poor malignancy prognosis
ii. It results from cancer driven increases in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma, and death.

iii. Denosumab acts by inhibiting the osteoclast mediated bone resorption, which results in decrease in bone destruction and calcium release, thus lowering calcium levels in HCM patients.

C. **Efficacy**

   *Please refer to most recent prescribing information.*

D. **Medication Safety Considerations**

   Boxed warning: No

   *Please refer to most recent prescribing information.*

E. **Dosing and administration**

   a. For the treatment of osteoporosis in postmenopausal women: 60 mg subcutaneously every 6 months (Prolia)
   
   b. For treatment of glucocorticoid-induced osteoporosis in men and women: 60 mg subcutaneously every 6 months (Prolia)
   
   c. For prevention of osteoporosis in men and women on hormone suppression therapy: 60 mg subcutaneously every 6 months (Prolia)
   
   d. For the prevention of skeletal-related events in patients with multiple myeloma or with bone metastases from solid tumors: 120 mg subcutaneously every 4 weeks (Xgeva)
   
   e. For the treatment of HCM: 120 mg subcutaneously every 4 weeks (Xgeva)

   *Please refer to most recent prescribing information.*

F. **How supplied**

   a. Prolia: Single-use prefilled syringe containing 60 mg in a 1 mL solution
   
   b. Xgeva: Single-use vial containing 120 mg in a 1.7 mL solution

**References:**

<table>
<thead>
<tr>
<th>#</th>
<th>Date</th>
<th>Change Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2</td>
<td>Effective Date: 11/7/2019</td>
<td>Policy update for: trial and failure of oral and IV bisphosphonates, trial and failure of preferred products, combination therapy for osteoporosis diagnosis</td>
</tr>
<tr>
<td>2.1</td>
<td>Effective Date: 08/15/2019</td>
<td>Policy update for Xgeva indications of multiple myeloma and solid tumors based on NCCN guidelines</td>
</tr>
<tr>
<td>2.0</td>
<td>Effective Date: 08/09/2018</td>
<td>Policy update added new Xgeva indication: multiple myeloma and new Prolia indication: glucocorticoid-induced osteoporosis</td>
</tr>
<tr>
<td>1.9</td>
<td>Effective Date: 05/03/2018</td>
<td>Annual Review of Medical Policy</td>
</tr>
<tr>
<td>1.8</td>
<td>Effective Date: 07/05/2017</td>
<td>PA added to MAPPO and BCNA for Prolia and Xgeva</td>
</tr>
<tr>
<td>1.7</td>
<td>Effective Date: 05/04/2017</td>
<td>Changes: Annual Review/Medicare Disclaimer added</td>
</tr>
<tr>
<td>1.6</td>
<td>Effective Date: 11/10/2016</td>
<td>Annual Review; No changes to criteria, document template updated.</td>
</tr>
<tr>
<td>1.5</td>
<td>Effective Date: 05/07/2015</td>
<td>Policy update added new indication: hypercalcemia of malignancy (HCM)</td>
</tr>
<tr>
<td>1.4</td>
<td>Effective Date: 08/14/2014</td>
<td>Criteria update to treatment of osteoporosis and including continuation of therapy</td>
</tr>
<tr>
<td>1.3</td>
<td>Effective Date: 05/02/2013</td>
<td>Criteria update</td>
</tr>
<tr>
<td>1.2</td>
<td>Effective Date: 01/22/2013</td>
<td>PA added to BCBS for Prolia and Xgeva</td>
</tr>
<tr>
<td>1.1</td>
<td>Effective Date: 11/08/2012</td>
<td>New Policy. PA added to BCN for Prolia and Xgeva</td>
</tr>
</tbody>
</table>

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or [http://dailymed.nlm.nih.gov/dailymed/index.cfm](http://dailymed.nlm.nih.gov/dailymed/index.cfm).